Novavax trial data: COVID-19 vaccine candidate 90.4% effective
Novavax intends to file for regulatory authorizations for its COVID-19 vaccine in the third quarter and remains on track to reach a manufacturing capacity of 100 million doses per month by the end of the third quarter.